Hey @DGlaucomflecken, need an MRI. Insurance exactly who you think it is. Saw the sign. Can you ask Texaco Mike to put in a good word with his cousin? Kinda wanna get it done sooner than later
Great work by Tutku Tazegul & @ChadTracyMD getting an intern boot camp up and running at @UIowa_urology! Clinical coverage 🏥 not sacrificed but learning accelerated💨!
@JSurgEduc
https://t.co/G51HJ1iILq
Wonderful to see global financial implications in bladder cancer care being formally discussed as #IBCG26@IBCG_BladderCA recommendation. @AmandaMyersMD discussed value and appropriate management with equal weight and rigor as oncologic outcomes. Outstanding. 🌎🙏👍
Resident physicians Brent Yelton, @vickyg_md, and Andrea Rossman worked with Dr. James A. Brown to author this review of Dr. Rubin H. Flocks's work with colloidal gold at Iowa, which helped pave the way to modern brachytherapy. Read it now in a special @NCSAUA issue of The Scope of Urology: https://t.co/XWsUDWuCLt
Our in-person interview dates for the 2026-27 residency recruitment season are set: 🗓️ November 10, December 8, and December 14.
Learn more about our residency program and what makes Iowa City such a great place to live: https://t.co/oC60XuQXHy
@uroacademic@Uro_Res@UroResidency
Congratulations to @AnnahVollstedt on achieving InterStim™ Center of Excellence designation, demonstrating exemplary use of the InterStim™ system to manage overactive bladder, urgency urinary incontinence, and urinary retention. We now have 3 providers with this designation, including @HenryLaiUro and Dr. Karl Kreder.
As I approach the end of my second maternity leave, I put together a peripartum resource guide for women physicians with a goal of helping colleagues navigate this rewarding but tricky time. Please use and circulate! https://t.co/DeROjGgHLb @SWIUorg@AMWADoctors
🚨 Half of focal therapy for #ProstateCancer in the US is happening where no guideline supports it 🚨
@JAMA_current research letter
👥 1,179,384 pts w/ nonmetastatic PCa, NCDB 2010 to 2023
📊 15,672 (1.3%) got focal therapy
⚠️ 51% was in low, high, or very high risk disease.
-No guideline supports routine use in ANY risk group outside trials or registries
⚠️ Low risk held flat (1.8% to 2.2%) and favorable intermediate is rising (2.1% to 2.9%) while marketing and&reimbursement expand
⚠️ Focal therapy more likely w/ age ≥75 (adjusted probability 22.9%), community centers (7.6% vs 2.5% academic), nonprivate insurance
✒️From the accompanying editorial
"Volume of this kind shows diffusion, not benefit."
🎯 Key points
1⃣In low risk this converts surveillance candidates into procedure pts
2⃣In high risk it is undertreatment.
3⃣Repeated use is building "an aura of legitimacy the data have not earned." We owe pts trials, not marketing.
🔗 Study: https://t.co/xbxCAXPfWE
🔗 Editorial: https://t.co/Nb0yjFHhSx
@QDTrinh@DrSpratticus@AmerUrological@UroOnc@SUO_YUO@urotoday@UrologyTimes@PCF_Science@PCFnews
Proud of this one. Hx of cystectomy+IC, open PNx. Now large stone burden. CT w retro renal spleen & existing PCN (27 cm SSD) in only reasonable access spot. Lower pole access achieved, pt stone free with PCNL. Complex cases alive and well at @UIowa_urology